Skip to main content
Bio Solution Co.,Ltd. logo

Bio Solution Co.,Ltd. — Investor Relations & Filings

Ticker · 086820 ISIN · KR7086820008 KO Manufacturing
Open in API
Filings indexed 215 across all filing types
Latest filing 2025-05-13 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 086820

About Bio Solution Co.,Ltd.

https://bio-solution.co.kr/

Bio Solution Co., Ltd. is a biotechnology company focused on the development, manufacturing, and sale of cell therapy products. The company's core activities involve cell-based biotechnology, producing therapeutics such as autologous chondrocyte treatments for cartilage regeneration. In addition to its therapeutic offerings, Bio Solution develops human tissue models and provides alternative testing solutions. The company also manufactures and distributes a portfolio of bio-laboratory products, including ready-to-use kits, staining solutions, and various reagents for molecular biology research and development applications.

Recent filings

Filing Released Lang Actions
주요사항보고서(무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from BioSolution regarding a 'Decision on Bonus Issue' (무상증자결정). This filing details a change in the company's capital structure through the issuance of new shares to existing shareholders. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'Share Issue/Capital Change' (SHA) category.
2025-05-13 Korean
주주명부폐쇄기간또는기준일설정
Share Issue/Capital Change Classification · 100% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder register closure, specifically for the purpose of a bonus issue (free share distribution). It does not contain the full financial report or the actual proxy materials, but rather serves as a formal notice of a corporate action. Given the nature of the announcement regarding share-related corporate actions and the lack of a specific category for 'Record Date' or 'Corporate Action Notice', it falls under the general regulatory filing category.
2025-05-13 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Corporate Day). It provides details such as the date, time, location, purpose, and participants. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into specific categories like 'Call Transcript' or 'Annual Report', it is classified as a Regulatory Filing (RNS) as it serves as a general corporate disclosure of an event.
2025-05-09 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (Corporate Day). It provides details such as the date, location, purpose, and participants. Since it is an announcement of an event rather than the presentation materials themselves, and it is under 5,000 characters, it falls under the category of a regulatory announcement regarding company activities.
2025-05-09 Korean
투자판단관련주요경영사항(임상시험결과) (카티라이프(바솔자가연골유래연골세포치료제)의 미국 2상 임상시험 최종결과보고서 수령)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure filed by BioSolution regarding the receipt of a final clinical trial report for its product 'Cartilife'. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean stock market (KRX), which is used to disclose material events such as clinical trial results. Since it does not fit into specific categories like financial reports, dividend notices, or board changes, and serves as a formal regulatory announcement of a material event, it is classified as a Regulatory Filing (RNS).
2025-05-07 Korean
투자판단관련주요경영사항 (카티라이프(바솔자가연골유래연골세포)의 한국 식품의약품안전처 품목 변경허가 획득)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' (투자판단 관련 주요경영사항) disclosure. It announces that the company, BioSolution, has received a product change approval from the Ministry of Food and Drug Safety (MFDS) for its product 'CartiLife'. Since this is a specific regulatory announcement regarding a material business event (product approval) and does not fit into categories like financial reports, dividends, or director dealings, it is classified as a general regulatory filing.
2025-04-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.